Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies

Susan Bal; Ehsan Malek; Ankit Kansagra; Saad Z. Usmani; Ravi Vij; Kelly N. Godby; Robert F. Cornell; Yubin Kang; Elvira Umyarova; Smith Giri; Saurabh Chhabra; Michaela Liedtke; Natalie S. Callander; Parameswaran Hari; Shaji Kumar; Luciano J. Costa

doi:10.1038/s41375-021-01471-3

Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies

Susan Bal, Ehsan Malek, Ankit Kansagra, Saad Z. Usmani, Ravi Vij, Kelly N. Godby, Robert F. Cornell, Yubin Kang, Elvira Umyarova, Smith Giri, Saurabh Chhabra, Michaela Liedtke, Natalie S. Callander, Parameswaran Hari, Shaji Kumar, Luciano J. Costa

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Original language	English
Pages (from-to)	877-880
Number of pages	4
Journal	Leukemia
Volume	36
Issue number	3
DOIs	https://doi.org/10.1038/s41375-021-01471-3
State	Published - Mar 2022

Access to Document

10.1038/s41375-021-01471-3

Cite this

Bal, S., Malek, E., Kansagra, A., Usmani, S. Z., Vij, R., Godby, K. N., Cornell, R. F., Kang, Y., Umyarova, E., Giri, S., Chhabra, S., Liedtke, M., Callander, N. S., Hari, P., Kumar, S., & Costa, L. J. (2022). Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia, 36(3), 877-880. https://doi.org/10.1038/s41375-021-01471-3

@article{63dc2b0f305f445ea273d313ec362f20,

title = "Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies",

author = "Susan Bal and Ehsan Malek and Ankit Kansagra and Usmani, {Saad Z.} and Ravi Vij and Godby, {Kelly N.} and Cornell, {Robert F.} and Yubin Kang and Elvira Umyarova and Smith Giri and Saurabh Chhabra and Michaela Liedtke and Callander, {Natalie S.} and Parameswaran Hari and Shaji Kumar and Costa, {Luciano J.}",

note = "Funding Information: EhM: Consultancy and Speakers Bureau (Takeda, Celgene, Amgen, Janssen); ML: Consultancy (Amgen/Onyx), Honoraria (Amgen/Onyx, Pfizer, Prothena, Takeda), Research Funding (Amgen/Onyx, BlueBirdBio, Celgene, Genentech/Roche, Gilead, Pfizer, Prothena, Takeda), Membership on an entity{\textquoteright}s Board of Directors or advisory committees (Caelum, Pfizer, Prothena, Takeda); PH: Consultancy and Research Funding (Amgen, Celgene), Honoraria (Celgene); RV: Honoraria (Celgene, Bristol Myers Squibb, Takeda, Amgen, Janssen, Karyopharma, Jazz), Research Funding (Celgene, Bristol Myers Squibb, Takeda); SU: Consultancy (Abbvie, Amgen, Celgene, Genmab, Merck, MundiPharma, Seattle Genetics), Research Funding (Amgen, BMS, Celgene, Janssen, Merck, Pharmacyclics, Takeda), Membership on an entity{\textquoteright}s Board of Directors or advisory committees (Sanofi); ShK: Consultancy (AbbVie, Celgene, Janssen, Kite Pharma, Merck, Takeda); LC: Honoraria (Amgen, Celgene, AbbVie), Research Funding (Amgen, Celgene, Janssen). SB has received research funding from Amyloid Foundation. SG is supported in part by the Walter B. Frommeyer Fellowship in Investigative Medicine at the University of Alabama at Birmingham and reports receiving research funding from Carevive Systems and Pack Health. SC: Research Funding: Amgen, Janssen, Sanofi; Honorarium: Glaxo Smith Kline. Other authors do not have any conflicts of interest to disclose.",

year = "2022",

month = mar,

doi = "10.1038/s41375-021-01471-3",

language = "English",

volume = "36",

pages = "877--880",

journal = "Leukemia",

issn = "0887-6924",

number = "3",

}

TY - JOUR

T1 - Treatment outcomes of triple class refractory multiple myeloma

T2 - a benchmark for new therapies

AU - Bal, Susan

AU - Malek, Ehsan

AU - Kansagra, Ankit

AU - Usmani, Saad Z.

AU - Vij, Ravi

AU - Godby, Kelly N.

AU - Cornell, Robert F.

AU - Kang, Yubin

AU - Umyarova, Elvira

AU - Giri, Smith

AU - Chhabra, Saurabh

AU - Liedtke, Michaela

AU - Callander, Natalie S.

AU - Hari, Parameswaran

AU - Kumar, Shaji

AU - Costa, Luciano J.

N1 - Funding Information: EhM: Consultancy and Speakers Bureau (Takeda, Celgene, Amgen, Janssen); ML: Consultancy (Amgen/Onyx), Honoraria (Amgen/Onyx, Pfizer, Prothena, Takeda), Research Funding (Amgen/Onyx, BlueBirdBio, Celgene, Genentech/Roche, Gilead, Pfizer, Prothena, Takeda), Membership on an entity’s Board of Directors or advisory committees (Caelum, Pfizer, Prothena, Takeda); PH: Consultancy and Research Funding (Amgen, Celgene), Honoraria (Celgene); RV: Honoraria (Celgene, Bristol Myers Squibb, Takeda, Amgen, Janssen, Karyopharma, Jazz), Research Funding (Celgene, Bristol Myers Squibb, Takeda); SU: Consultancy (Abbvie, Amgen, Celgene, Genmab, Merck, MundiPharma, Seattle Genetics), Research Funding (Amgen, BMS, Celgene, Janssen, Merck, Pharmacyclics, Takeda), Membership on an entity’s Board of Directors or advisory committees (Sanofi); ShK: Consultancy (AbbVie, Celgene, Janssen, Kite Pharma, Merck, Takeda); LC: Honoraria (Amgen, Celgene, AbbVie), Research Funding (Amgen, Celgene, Janssen). SB has received research funding from Amyloid Foundation. SG is supported in part by the Walter B. Frommeyer Fellowship in Investigative Medicine at the University of Alabama at Birmingham and reports receiving research funding from Carevive Systems and Pack Health. SC: Research Funding: Amgen, Janssen, Sanofi; Honorarium: Glaxo Smith Kline. Other authors do not have any conflicts of interest to disclose.

PY - 2022/3

Y1 - 2022/3

UR - http://www.scopus.com/inward/record.url?scp=85119448679&partnerID=8YFLogxK

U2 - 10.1038/s41375-021-01471-3

DO - 10.1038/s41375-021-01471-3

M3 - Article

C2 - 34802043

AN - SCOPUS:85119448679

SN - 0887-6924

VL - 36

SP - 877

EP - 880

JO - Leukemia

JF - Leukemia

IS - 3

ER -

Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies

Access to Document

Other files and links

Cite this